![CRISPR/Cas-mediated plant genome editing: outstanding challenges a decade after implementation: Trends in Plant Science CRISPR/Cas-mediated plant genome editing: outstanding challenges a decade after implementation: Trends in Plant Science](https://www.cell.com/cms/attachment/29ae3bb4-941b-46ef-9d4f-8d69fba19d8f/gr1.jpg)
CRISPR/Cas-mediated plant genome editing: outstanding challenges a decade after implementation: Trends in Plant Science
![Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial - The Lancet Oncology Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/6675c02e-0aaf-44bb-9407-4829950dba50/gr1.gif)
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial - The Lancet Oncology
![The geography of COVID-19 spread in Italy and implications for the relaxation of confinement measures | Nature Communications The geography of COVID-19 spread in Italy and implications for the relaxation of confinement measures | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-020-18050-2/MediaObjects/41467_2020_18050_Fig1_HTML.png)
The geography of COVID-19 spread in Italy and implications for the relaxation of confinement measures | Nature Communications
STECF 13-07 - DCF NPs guidelines plus MS reports.pdf - Data Collection Framework - European Commission
![Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet](https://www.thelancet.com/cms/asset/ed8fc363-c6de-4dbe-bc2d-1aea4a4870bf/gr1.jpg)
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet
![Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial | Nature Medicine Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-023-02321-8/MediaObjects/41591_2023_2321_Fig1_HTML.png)
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial | Nature Medicine
![Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial - The Lancet Oncology Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/209b827d-c7bc-4235-8c71-c999e28e9c68/gr1.jpg)
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial - The Lancet Oncology
![Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study - The Lancet Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study - The Lancet](https://www.thelancet.com/cms/asset/aee99cbc-80a0-49e4-9ac3-6cc4f16265f9/gr1.jpg)
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study - The Lancet
![Amazon.com: LAUNCH Creader 3001 OBD2 Scanner, Engine Fault Code Reader Mode 6 CAN Diagnostic Scan Tool for All OBDII Protocol Cars Since 1996, Lifetime Free Update : Automotive Amazon.com: LAUNCH Creader 3001 OBD2 Scanner, Engine Fault Code Reader Mode 6 CAN Diagnostic Scan Tool for All OBDII Protocol Cars Since 1996, Lifetime Free Update : Automotive](https://images-na.ssl-images-amazon.com/images/I/81kLbtf+m+L._AC_UL210_SR210,210_.jpg)
Amazon.com: LAUNCH Creader 3001 OBD2 Scanner, Engine Fault Code Reader Mode 6 CAN Diagnostic Scan Tool for All OBDII Protocol Cars Since 1996, Lifetime Free Update : Automotive
![A RANDOMIZED TRIAL COMPARING RIBAVIRIN DOSE REDUCTION VERSUS ERYTHROPOIETIN FOR ANEMIA MANAGEMENT IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC HEPATITIS C RECEIVING BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN A RANDOMIZED TRIAL COMPARING RIBAVIRIN DOSE REDUCTION VERSUS ERYTHROPOIETIN FOR ANEMIA MANAGEMENT IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC HEPATITIS C RECEIVING BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN](https://www.natap.org/2012/images/042312/042312-2/EASL1.gif)